BioCentury
ARTICLE | Finance

Dampening expectations

August 16, 1993 7:00 AM UTC

Noteworthy

Regeneron Pharmaceuticals Inc. stock responded negatively to the company's disclosure last week that there was no significant difference between drug and placebo in its Phase II trial of ciliary neurotrophic factor to treat amyotrophic lateral sclerosis. But the small size of the trial makes it impossible to draw many conclusions about CNTF's efficacy...